| 1 |
任成山，钱桂生. 慢性阻塞性肺疾病发病机制研究现状与展望[J/CD]. 中华肺部疾病杂志(电子版), 2009, 2(2): 104-115.
|
| 2 |
GOLD Executive Committee. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Lung Disease (Updated 2013)[EB/OL]. [2013-2-20].
URL
|
| 3 |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志，2013, 36(4): 255-264.
|
| 4 |
Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD[J]. Eur Respir J, 2008, 32(5): 1371-1385.
|
| 5 |
Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation：a systemic review and a metaanalysis[J]. Thorax, 2004, 59(1): 574-580.
|
| 6 |
Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement in COPD[J]. Chest, 2008, 134(4): 808-814.
|
| 7 |
Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension[J]. Chest, 2006, 130(2): 326-333.
|
| 8 |
Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells[J]. Circulation, 2002, 106(12): 1439-1441.
|
| 9 |
Zakynthinos E, Daniil Z, Papanikolaou J, et al. Pulmonary hypertension in COPD pathophysiology and therapeutic targets[J]. Curr Drug Targets, 2011, 12(4): 501-513.
|
| 10 |
Barberà JA, Peinado Vl, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease[J]. Eur Respir J, 2003, 21: 892-905.
|
| 11 |
Carratu P, Scoditti C, Maniscalco M, et al. Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension[J]. BMC Pulm Med, 2008, 8: 20.
|
| 12 |
Lee JH, Cho MH, Hersh CP, et al. IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease[J]. Am J Respir Cell Mol Biol, 2015, 52(3): 365-376.
|
| 13 |
徐凌，蔡柏蔷. 慢性阻塞性肺疾病合并肺动脉高压诊断和治疗的新认识[J]. 国际呼吸杂志，2009, 29(6): 326-330.
|
| 14 |
Chaouat A, Bugnet AS, Kadaoui N, et al. Weitzenblum E: Severe pulmonary hypertension and chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2005, 172(2): 189-194.
|
| 15 |
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension：the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS)endorsed by：Association for European Paediatric and Congenital Cardiology(AEPC), International Society for Heart and Lung Transplantation(ISHLT)[J]. Eur Heart J, 2016, 37(1): 67-119.
|
| 16 |
Vonk-Noordegraaf A, Souza R. Cardiac magnetic resonance imaging：what can it add to our knowledge of the right ventricle in pulmonary arterial hypertension[J]. Am J Cardiol, 2012, 110(6Suppl): 25S-31S.
|
| 17 |
Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension[J]. Am J Respir Crit Care Med, 2010, 181(3): 270-278.
|
| 18 |
Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017 report [EB/OL]. 2016-11-16[2016-12-09].
URL
|
| 19 |
Vitulo P, Stanziola A, Confalonieri M, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial[J]. J Heart Lung Transplant, 2017, 36(2): 166-174.
|
| 20 |
Blanco L, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial[J]. Eur Respir J, 2013, 42(4): 982-992.
|
| 21 |
Stolz D, Rasch H, Linka A, et al. A randomized, controlled trial of bosentan in severe COPD[J]. Eur Respir J, 2008, 32(3): 619-628.
|
| 22 |
Lee TM, Chen CC, Shen HN, et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension[J]. Clin Sci(Lond), 2009, 116(16): 497-505.
|
| 23 |
Reed RM, Lacono A, Defilippis A, et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD[J]. COPD, 2011, 8(2): 96-102.
|
| 24 |
Criner GJ, Connett JE, Aaron SD, et al. Simbastatin for the prevention of exacerbations in moderate-to-severe COPD[J]. N Engl J Med, 2014, 370(23): 2201-2210.
|
| 25 |
Eberhardt R, Gerovasili V, Kontogianni K, et al. Endoscopic lung volume reduction with endobronchial valves in patients with severe emphysema and established pulmonary hypertension[J]. Respiration, 2015, 89(1): 41-48.
|
| 26 |
Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction Surgery with medical therapy for severe emphysema[J]. N Engl J Med, 2003, 348(21): 2059-2073.
|